RAD-SG Trial Evaluates RADiation Therapy and Sacituzumab Govitecan in MIBC
October 6th 2023Omar Mian, MD, PhD, provides an overview of the RAD-SG trial of RADiation therapy given with sacituzumab govitecan for bladder preservation in patients with muscle-invasive bladder cancer, which is currently in progress.
Watch
Overview on Advances in GI Malignancy Management with Precision Medicine
October 6th 2023Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, discuss recent updates in the management of gastrointestinal malignancies, with a focus on colorectal cancer and the crucial role of precision medicine in guiding treatment decisions.
Watch
Managing Treatment-Related Side Effects of Tisotumab Vedotin
October 2nd 2023Ramez N. Eskander, MD, discusses the importance of understanding and managing treatment-related adverse events, including ocular side effects, bleeding, and neuropathy, associated with the innovative therapy tisotumab vedotin in cervical cancer patients.
Watch
Tisotumab Vedotin: Advancing Cervical Cancer Treatment
October 2nd 2023Perspectives on the breakthrough antibody drug conjugate, tisotumab vedotin, its mechanism of action, and the significant clinical benefits it offers to patients with recurrent or metastatic cervical cancer, leading to FDA approval and promising results in a confirmatory trial.
Watch
Recurrent Cervical Cancer Treatment Evolution: Immunotherapy and Beyond
October 2nd 2023Ramez N. Eskander, MD, explores evolving treatment options, including immunotherapy and antibody drug conjugates, in recurrent cervical cancer, highlighting the importance of biomarkers and clinical trials in this dynamic landscape.
Watch
Revolutionizing Frontline Cervical Cancer Treatment: Trials to Transformative Therapies
October 2nd 2023An overview of the remarkable evolution in the treatment landscape for metastatic and recurrent cervical cancer patients, shaped by pivotal clinical trials and the integration of immunotherapy, resulting in significantly improved clinical outcomes.
Watch
Biomarkers in Cervical Cancer: Guiding Innovative Treatments
October 2nd 2023A key opinion leader explores the significance of biomarkers, including PD-L1 CPS score, TMB, MSI, and HER2, in shaping advanced treatment strategies for cervical cancer patients, emphasizing personalized care and clinical trial opportunities.
Watch
Coming Soon: Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
September 29th 2023Expert Matthew Lunning, DO, FACP, shares his excitement for an upcoming case-based peer perspectives program wherein he reviews the diagnosis and management of a patient with DLBCL, considering evolving treatment paradigms and updated clinical data.
Watch
CAR T Cells and Bispecifics Generate Excitement in Multiple Myeloma
September 29th 2023Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.
Watch
Case Overview: A 62-Year-Old Woman with Squamous Histology and PD-L1 Negative mNSCLC
September 29th 2023Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.
Watch
Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS
September 29th 2023Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.
Watch
The Future of Patient Care in RRMM
September 28th 2023Dr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.
Watch